Research programme: tuberculosis vaccine - Stressgen Biotechnologies
Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Nventa Biopharmaceuticals Corporation; Postgraduate Institute of Medical Education and Research Chandigarh
- Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Tuberculosis in India (unspecified route)
- 05 Sep 2006 Discontinued - Preclinical for Tuberculosis in USA (unspecified route)
- 01 May 1997 Preclinical development for Tuberculosis in India (unspecified route)